What is Nucleix?
Nucleix is a pioneering liquid biopsy company dedicated to revolutionizing cancer treatment through earlier disease detection. By utilizing a sophisticated combination of NGS and PCR-based epigenetics, the company identifies cancer markers with high precision. Its flagship EpiCheck platform offers a non-invasive, highly sensitive alternative to traditional diagnostic methods, providing a seamless experience for both patients and healthcare providers. Currently, the company is scaling its commercial footprint with the Bladder EpiCheck testing kit in Europe while simultaneously advancing its Lung EpiCheck test toward broader market adoption. This strategic focus on high-risk diseases places Nucleix at the forefront of the molecular diagnostics market, bridging the gap between laboratory innovation and clinical application.
How much funding has Nucleix raised?
Nucleix has raised a total of $85M across 4 funding rounds:
Unspecified
$5M
Unspecified
$3M
Other Financing Round
$55M
Other Financing Round
$22M
Unspecified (2014): $5M with participation from OrbiMed Advisors LLC
Unspecified (2016): $3M led by Aurum and OrbiMed Israel Partners
Other Financing Round (2021): $55M supported by BlackRock, MILFAM, DSC Investment, LYFE Capital, OrbiMed, Aurum Ventures Private, OCI Bio Investments, RA Capital Management, Lilly Asia Ventures, and Zohar Zisapel
Other Financing Round (2022): $22M featuring Sands Capital
Key Investors in Nucleix
OrbiMed Israel Partners
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics to support innovation from early-stage ventures to established organizations.
BlackRock
BlackRock is a global investment management firm providing institutional clients with diverse investment strategies across equities, fixed income, and alternative assets.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing diagnostics and research tools.
What's next for Nucleix?
With the support of major institutional backers, Nucleix is entering a critical phase of enterprise-level scaling. The company's roadmap focuses on the commercialization of its pipeline, specifically targeting the expansion of the Lung EpiCheck test for high-risk individuals. Future strategic initiatives will likely involve deepening its clinical evidence base and strengthening its market presence in key global territories. As the firm continues to refine its methylation-based identification techniques, it remains well-positioned to capture significant market share in the rapidly evolving landscape of early-stage cancer diagnostics, ultimately aiming to improve patient outcomes through timely and actionable clinical insights.
See full Nucleix company page
